Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: A randomised prospective phase II trial

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Skof, Erik ^a   Rebersek, Martina ^a   Hlebanja, Zvezdana ^a   Ocvirk, Janja ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STEATOSIS; THROMBOCYTOPENIA; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; COMPARATIVE STUDY; LIVER TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DIARRHEA; FATIGUE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; NEOADJUVANT THERAPY; NEUTROPENIA; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 65649149767     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-120     Document Type: Article

References (22)

1. Abdalla EK Vauthey JN Ellis LM Ellis V Pollock R Broglio KR Hess K Curley SA Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases Ann Surg 2004, 239:818-825. 1356290 15166961 10.1097/ 01.sla.0000128305.90650.71
2. Wei AC Greig PD Grant D Taylor B Langer B Gallinger S Survival after hepatic resection for colorectal metastases: A 10-year experience Ann Surg Oncol 2006, 13:668-676. 10.1245/ASO.2006.05.039 16523369
3. Simmonds PC Primrose JN Colquitt JL Garden OJ Poston GJ Rees M Surgical resection of hepatic metastases from colorectal cancer: A systematic review of published studies Br J Cancer 2006, 94:982-999. 10.1038/ sj.bjc.6603033 16538219
4. Cummings LC Payes JD Cooper GS Survival after hepatic resection in metastatic colorectal cancer: A population-based study Cancer 2007, 109:718-726. 10.1002/cncr.22448 17238180
5. Van Cutsem E Nordlinger B Adam R Köhne CH Pozzo C Poston G Ychou M Rougier P European Colorectal Metastases Treatment. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases Eur J Cancer 2006, 42:2212-2221. 10.1016/ j.ejca.2006.04.012 16904315
6. Masi G Cupini S Marcucci L Cerri E Loupakis F Allegrini G Brunetti IM Pfanner E Viti M Goletti O Filipponi F Falcone Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer Ann Surg Oncol 2006, 13:58-56. 10.1245/ ASO.2006.03.094 16372158
7. Alberts SR Horvath WL Sternfeld WC Goldberg RM Mahoney MR Dakhil SR Levitt R Rowland K Nair S Sargent DJ Donohue Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Arm Phase II Study J Clin Oncol 2005, 23:9243-9249. 10.1200/JCO.2005.07.740 16230673
8. Barone C Nuzzo G Cassano A Basso M Schinzari G Giuliante F D'Argento E Trigila N Astone A Pozzo Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases Br J Cancer 2007, 97:1035-1039. 10.1038/sj.bjc.6603988 17895897
9. Porschen R Arkenau HT Kubicka S Greil R Seufferlein T Freier W Kretzschmar A Graeven U Grothey A Hinke A Schmiegel W Schmoll HJ AIO Colorectal Study Arm Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin: A Randomized Comparison in Metastatic Colorectal Cancer - A Final Report of the AIO Colorectal Study Arm J Clin Oncol 2007, 25:4217-4223. 10.1200/JCO.2006.09.2684 17548840
10. Diaz-Rubio E Tabernero J Gomez-Espana A Massutí B Sastre J Chaves M Abad A Carrato A Queralt B Reina JJ Maurel J González-Flores E Aparicio J Rivera F Losa F Aranda E Spanish Cooperative Arm for the Treatment of Digestive Tumors Trial Phase III Study of Capecitabine Plus Oxaliplatin Versus Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Arm for the Treatment of Digestive Tumors Trial J Clin Oncol 2007, 25:4224-4230. 10.1200/JCO.2006.09.8467 17548839
11. Patt YZ Lee FC Leibmann JE Diamandidis D Eckhardt SG Javle M Justice GR Keiser W Salvatore JR Bexon A Lin E Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer Am J Clin Oncol 2007, 30:350-357. 10.1097/ COC.0b013e31804b40bb 17762434
12. Bajetta E Di Bartolomeo M Mariani L Cassata A Artale S Frustaci S Pinotti G Bonetti A Carreca I Biasco G Bonaglia L Marini G Iannelli A Cortinovis D Ferrario E Beretta E Lambiase A Buzzoni R Italian Trials in Medical Oncology (I.T.M.O.) Arm Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma Cancer 2004, 100:279-287. 10.1002/cncr.11910 14716761
13. Borner MM Bernhard J Dietrich D Popescu R Wernli M Saletti P Rauch D Herrmann R Koeberle D Honegger H Brauchli P Lanz D Roth AD Swiss Arm for Clinical Cancer Research (SAKK), Berne, Switzerland A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: Efficacy, quality-of-life and toxicity Ann Oncol 2005, 16:282-288. 10.1093/annonc/ mdi047 15668285
14. Rea DW Nortier JW Ten Bokkel Huinink WW Falk S Richel DJ Maughan T Groenewegen G Smit JM Steven N Bakker JM Semiond D Kerr DJ Punt CJ A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer Ann Oncol 2005, 16:1123-1132 10.1093/annonc/mdi227 15939714
15. Therasse P Arbuck SG Eisenhauer EA Wanders J Kaplan RS Rubinstein L Verweij J Van Glabbeke M van Oosterom AT Christian MC Gwyther SG New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205 10655437
16. Kaplan E Meier P Nonparametric estimation from incomplete observations J Am Stat Assoc 1958, 53:457-481. 10.2307/2281868
17. Van Cutsem E Bodoky G Roh JK Folprecht G Park YS Van Laethem JL Raoul JL Ciardiello F Lebrun P Rougier P CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC) [abstract] Eur J Cancer 2007, 5(Suppl 4):235.
18. Tournigand C Andre T Achille E Lledo G Flesh M Mery-Mignard D Quinaux E Couteau C Buyse M Ganem G Landi B Colin P Louvet C de Gramont A FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study J Clin Oncol 2004, 22:229-237. 10.1200/ JCO.2004.05.113 14657227
19. Colucci G Gebbia V Paoletti G Giuliani F Caruso M Gebbia N Carteni G Agostara B Pezzella G Manzione L Borsellino N Misino A Romito S Durini E Cordio S Di Seri M Lopez M Maiello E Montemurro S Cramarossa A Lorusso V Di Bisceglie M Chiarenza M Valerio MR Guida T Leonardi V Pisconti S Rosati G Carrozza F Nettis G Valdesi M Filippelli G Fortunato S Mancarella S Brunetti C Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale J Clin Oncol 2005, 23:4866-75. 10.1200/JCO.2005.07.113 15939922
20. Koopman M Antonini NF Douma J Wals J Honkoop AH Erdkamp FL de Jong RS Rodenburg CJ Vreugdenhil G Loosveld OJ van Bochove A Sinnige HA Creemers GJ Tesselaar ME Slee PH Werter MJ Mol L Dalesio O Punt CJ Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial Lancet 2007, 370:135-142. 10.1016/ S0140-6736(07)61086-1 17630036
21. Fuchs CS Marshall J Mitchell E Wierzbicki R Ganju V Jeffery M Schulz J Richards D Soufi-Mahjoubi R Wang B Barrueco J Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study J Clin Oncol 2007, 25:4779-4786. 10.1200/JCO.2007.11.3357 17947725
22. Folprecht G Gruenberger T Hartmann JT Lordick F Stoehlmacher J Bechstein W Ockert D Hermann T Liersch T Koehne C Randomized multicenter study of cetuximab plus FOLFOX of plus FOLFIRI in neoadjuvant treatment of non-resectable colorectal liver metastases (CELIM-study) Ann Oncol 2007, 19(Suppl 8):vIii168.